As of 2026-03-18, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -4.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 392.38 mil USD. KPTI's TTM EBITDA according to its financial statements is -90.26 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.5x - 17.9x | 14.7x |
| Forward P/E multiples | 17.6x - 22.5x | 20.3x |
| Fair Price | (99.53) - (101.11) | (99.14) |
| Upside | -1287.8% - -1306.5% | -1283.1% |
| Date | EV/EBITDA |
| 2026-03-13 | -4.24 |
| 2026-03-12 | -4.25 |
| 2026-03-11 | -4.42 |
| 2026-03-10 | -4.32 |
| 2026-03-09 | -4.37 |
| 2026-03-06 | -4.43 |
| 2026-03-05 | -4.44 |
| 2026-03-04 | -4.50 |
| 2026-03-03 | -4.50 |
| 2026-03-02 | -4.59 |
| 2026-02-27 | -4.56 |
| 2026-02-26 | -4.54 |
| 2026-02-25 | -4.69 |
| 2026-02-24 | -4.69 |
| 2026-02-23 | -4.68 |
| 2026-02-20 | -4.61 |
| 2026-02-19 | -4.61 |
| 2026-02-18 | -4.52 |
| 2026-02-17 | -4.55 |
| 2026-02-13 | -4.39 |
| 2026-02-12 | -4.46 |
| 2026-02-11 | -4.14 |
| 2026-02-10 | -3.98 |
| 2026-02-09 | -3.93 |
| 2026-02-06 | -3.92 |
| 2026-02-05 | -3.88 |
| 2026-02-04 | -3.92 |
| 2026-02-03 | -3.98 |
| 2026-02-02 | -3.93 |
| 2026-01-30 | -3.97 |
| 2026-01-29 | -3.99 |
| 2026-01-28 | -4.05 |
| 2026-01-27 | -4.08 |
| 2026-01-26 | -4.00 |
| 2026-01-23 | -3.98 |
| 2026-01-22 | -3.99 |
| 2026-01-21 | -3.93 |
| 2026-01-20 | -3.85 |
| 2026-01-16 | -3.93 |
| 2026-01-15 | -4.00 |
| 2026-01-14 | -4.11 |
| 2026-01-13 | -4.25 |
| 2026-01-12 | -4.31 |
| 2026-01-09 | -4.41 |
| 2026-01-08 | -4.30 |
| 2026-01-07 | -4.24 |
| 2026-01-06 | -4.14 |
| 2026-01-05 | -4.15 |
| 2026-01-02 | -4.11 |
| 2025-12-31 | -4.14 |